[0] Incyte Sets Announcement Date for Fourth Quarter Fiscal 2001 Earnings Release.

Business Editors

PALO ALTO, Calif.--(BUSINESS WIRE)--Feb. 4, 2002

Incyte Genomics, Inc. (Nasdaq:INCY), the leading genomic information company, announced today its intention to release fourth quarter fiscal year 2001 earnings results on Wednesday, February 13, 2001 after the close of the stock market.

Company management will host a conference call on Wednesday, February 13, 2002 at 2:00 p.m. PST to discuss the company's results. The domestic dial in number for the conference call will be 877/692-2588 and the international dial in number will be 973/872-3462. A replay of the conference call will be available through February 20, 2002 (12:00 midnight PST). The replay dial in number for both U.S. and International callers will be 973/341-3080 and the PIN number access code will be 3099979.

A webcast will be distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network such as America Online's Personal Finance Channel. Institutional investors can access the call via CCBN's password protected event management site, StreetEvents (www.streetevents.com).

Incyte Genomics, Inc. has developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. In addition, Incyte has the largest portfolio of issued United States patents covering human full-length genes and the proteins they encode and is leveraging its intellectual property position to be a leader in therapeutic discoveries. For more information, visit Incyte's web site at http://www.incyte.com.

Except for the historical information contained herein, the matters set forth in this press release, including without limitation statements as to the Company's intended earnings announcement date, the ability of Incyte's products and services to enhance the research efforts of its customers and Incyte's ability to leverage its intellectual property position to become a leader in therapeutic discoveries, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including scheduling conflicts; the impact of competition and alternative technologies, processes and approaches on Incyte's business; Incyte's ability to compete against competitors that may have greater financial or other resources; changes in consumer demand for Incyte's products and services; changes in Incyte's business plan; Incyte's ability to obtain patent protection for its discoveries and to continue to be effective in expanding its patent coverage; and other risks detailed from time to time in Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2001. Incyte disclaims any intent or obligation to update these forward-looking statements.